Filing Flows › Karyopharm Therapeutics (KPTI) › Q1 2025
Karyopharm Therapeutics (KPTI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Karyopharm Therapeutics (KPTI) reported revenue of $30.0M for the first quarter 2025 (Q1 2025), -9% from a year earlier and -2% from the quarter before. Operating margin was -110.8%, net loss $23.5M (78.2% of revenue).
Karyopharm Therapeutics, Q1 2025: revenue $30.0M (-9% year over year), operating margin -110.8%, net loss $23.5M, operating cash flow −$39.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.0M | -2% | -9% |
| Operating profit | −$33.3M | — | — |
| Net earnings | −$23.5M | — | — |
| Operating cash flow | −$39.0M | — | — |
What changed
Revenue was $30.0M in Q1 2025, down 9% year over year and down 2% from the previous quarter. Product was the largest line at 70% of revenue. Product lost $5.0M year over year (down 19%), 159% of the total change.
Operating costs exceeded revenue by $33.3M, an operating margin of -110.8%. Total costs fell 5% while revenue fell 9%. The quarter ended with a net loss of $23.5M, narrower than the previous quarter's $30.8M loss. Non-operating items added $9.8M, -42% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$39.0M. Non-cash charges added back $78K of depreciation and $3.6M of share-based compensation. Working capital and other items used $19.2M.
Questions
What was Karyopharm Therapeutics' revenue in the first quarter 2025?
Karyopharm Therapeutics (KPTI) reported revenue of $30.0M for the first quarter 2025 (Q1 2025), -9% from a year earlier and -2% from the quarter before.
Was Karyopharm Therapeutics profitable in the first quarter 2025?
Operating loss was $33.3M (-110.8% of revenue) and net loss $23.5M.